GSK presents data from Phase III STABILITY study of darapladib in patients with chronic coronary heart disease

GlaxoSmithKline plc (LSE/NYSE: GSK) today presented data from the pivotal Phase III STABILITY study of darapladib at the American College of Cardiology 63rd Annual Scientific Session in Washington, DC
Source: GSK news - Category: Pharmaceuticals Source Type: news